Hemoglobinuria Clinical Trial
— EXPLOREOfficial title:
P06-001: (EX)Amination of (P)NH, by (L)Evel (O)f CD59 on (RE)d and White Blood Cells, in Bone Marrow Failure Syndromes
| NCT number | NCT01192425 |
| Other study ID # | P06-001 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | August 30, 2010 |
| Last updated | August 31, 2010 |
| Verified date | August 2010 |
| Source | Alexion Pharmaceuticals |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Institutional Review Board |
| Study type | Observational |
Examine red and white blood cells of PNH patients with bone marrow failure syndromes.
| Status | Completed |
| Enrollment | 5580 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 10 Years and older |
| Eligibility |
Inclusion Criteria: - At least 10 years of age. - Has aplastic anemia, myelodysplastic syndromes or other bone marrow failure syndromes Exclusion Criteria: - Has any condition that might interfere with the patient's participation |
Time Perspective: Prospective
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Alexion Pharmaceuticals |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01642979 -
Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria
|
Phase 2 | |
| Active, not recruiting |
NCT01760096 -
Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)
|
Phase 2 | |
| Completed |
NCT00592657 -
Incidence of Rhabdomyolysis Among Patients Admitted With Jimsonweed Ingestions
|
N/A |